preclinical research results showing that 2ME2 has disease modifying or
"DMARD" activity, The FDA has accepted EntreMed's IND for 2ME2 in RA,
which included an extensive human safety dossier in 300 patients from
the oncology studies. Panzem(R) for RA represents a safe, orally
administered, small molecule alternative to current biologicals and a
potential "first-in-class" cross-over opportunity from oncology. The
Company plans to initiate a normal volunteer clinical trial in 2008
and seek a development partner to manage larger multi-arm Phase 2 and
Phase 3 studies.
EntreMed President & CEO, James S. Burns, commented, "We are concentrating our resources on fewer programs that we believe have greater potential for product registration and ultimately commercialization. We have three promising oncology programs to pursue in 2008: MKC-1 in multiple Phase 1 and 2 trials, ENMD-1198 that we expect to enter into Phase 2 before year end, and ENMD-2076 that will begin a Phase 1b clinical trial shortly, together with our initial clinical trial for Panzem(R) in a potentially larger RA market."
Mr. Burns further commented, "Our goal in 2008 is to continue moving ahead on priority programs while maintaining our cash expenditures at approximately the same level as in 2007. As part of our financial plan, we are also focusing increased attention on partnering one or more of our programs in order to fund and advance our programs into later stages of development. We will, however, continue to selectively seek opportunities such as individual products or companies that could favorably impact the quality of our pipeline, allow us to de-risk the Company, and enhance shareholder value."
A digital recording of the Company's will be available approximately
two hours after the completion of the conference and will be accessible for
60 days. To access the rec
|SOURCE EntreMed, Inc.|
Copyright©2008 PR Newswire.
All rights reserved